Trial reportChinese journal of integrative medicine2026
Andrographolide Sulfonate Injection for Adjunctive Treatment of Non-severe Community-Acquired Pneumonia in Adults: A Multicenter, Double-Blind, Randomized Controlled Trial.
Trial report in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02913118 (Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial
Who cites it
1 citing paper in PubMed.
- Berberine Suppresses Inflammatory Response in Severe Pneumonia by Specifically Targeting Upregulation of SIRT1 to Activate Nrf2 Signaling Pathway.Chinese journal of integrative medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect and safety of Andrographolide Sulfonate (AS) Injection for adjunctive treatment of non-severe community-acquired pneumonia (CAP) in adults.
methodsThis is a multicenter, randomized, double-blind, and placebo-controlled trial. Adult patients with non-severe CAP were randomly assigned in a 1:1 ratio to the AS or control group using a stratified block randomization method. Patients received either intravenous AS Injection (500 mg once per day) or placebo for 5 d. Both groups were treated with guideline-based standard therapy simultaneously. The primary outcome was time to clinical stability. Secondary outcomes were initial treatment failure rate, time to fever recovery, length of hospital stay, duration of intravenous antibiotic treatment, and cost of hospitalization. Safety outcomes included adverse events (AEs) and serious AEs.
resultsFrom September 2016 to April 2019, 482 patients were randomized into AS or control group (241 cases per group), and all were included in the intention-to-treat (ITT) analysis. The median time to clinical stability was 1 h shorter in the AS group than that in the control group [hazard ratio (HR) 1.440; 95% confidence interval (CI) 1.194, 1.736; log rank P<0.01]. AS group had 5 h shorter median time to fever recovery than the control group (HR 1.461; 95% CI 1.150, 1.857; log rank P<0.01). The initial treatment failure rate was significantly lower in the AS group than that in the control group (6.3% vs. 16.0%, P<0.01). There was no statistically significant difference in the length of hospital stay, duration of intravenous antibiotics treatment, and cost of hospitalization between groups (P>0.05). The proportion of patients with at least 1 AE was 41.5% in the AS group and 40.6% in the control group.
conclusionsAdjunctive AS Injection probably accelerates the clinical stability and lowers the initial treatment failure rate in adult hospitalized patients with non-severe CAP, but the absolute clinical benefits are marginal. Its use should take into account efficacy, safety, cost, and Chinese medicine syndrome classification. (Trial registration No. NCT02913118).
Indexed as
Identifiers
41489779What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.